819 Capital (operators-first micro VC)

819-capital.com

VCMatch tracks 819 Capital (operators-first micro VC) as an investor focused on Digital Health, Medtech, and Biotech companies, Pre-Seed and Seed rounds, Netherlands, Europe, and International markets, and $85m to $500m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$85m to $500m

Stages

Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage

Focus Areas

Digital Health, Medtech, Biotech

Geography

Netherlands, Europe, and International

Investment Thesis

819 Capital Partners pursues a sector-focused, multi-stage investment philosophy that combines patient capital with hands-on operational support. The firm seeks to drive “innovation, growth and value creation” by investing across venture, growth and private equity (including buy-and-build) while prioritizing societal impact—especially in healthcare, technology (deep-tech) and leisure. Across stages they emphasize strong management teams, defensible market positions, and the specific value 819 can add (operational improvements, M&A, networks) to scale companies and mitigate risk.

Is 819 Capital (operators-first micro VC) right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

819 Capital (operators-first micro VC) is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Digital Health, Medtech, Biotech, and Pharma, especially across Netherlands, Europe, and International, with public check-size signals around $85m to $500m.

Focus statement

819 Capital Partners prioritizes healthcare, technology (with an explicit focus on deep-tech, med‑tech, bio‑tech, advanced materials and AI) and leisure, deploying capital via an evergreen venture fund for early‑stage deep‑tech and private equity buy‑and‑build strategies for more mature platforms.

Value Add

Evergreen patient‑capital model: "Since our foundation, we have focused on providing long-term capital through our ‘evergreen fund’ model."
Multi-stage, integrated platform (venture → private equity → M&A/valuation) allowing cross‑stage support and synergies: "At our firm all activities are in sync and come together."
Active buy‑and‑build expertise and platform scaling demonstrated by multiple add‑on acquisitions (e.g., Chalet.nl, Fox Reizen, Insolution Group) and asset transactions (Lead Pharma).
Hands‑on, tailored involvement from a small efficient team: "We operate with a small, but efficient team...we work efficiently and tailor our involvement to the needs of our portfolio companies."
High professional standards & valuation expertise via memberships (NVP, NiRV) reinforcing disciplined deal execution and valuation.
Geographic and sector focus on the Netherlands and Dutch deeptech ecosystem (acquired funds containing stakes in 23 Dutch deeptech companies).